Alexander McNamara - Concepedia

Author

Alexander McNamara

Also Known As

A McNamara, A. McNamara, A.J. Mcnamara, ALEXANDER McNAMARA, Alexander J McNamara, Alexander McNamara, Alexander Mcnamara, Avery D. McNamara, Avery McNamara

Publications

465

Citations

H-Index

Concepts

All Affiliations

Theravance Biopharma (United States)

About

Alexander McNamara is an author at Theravance Biopharma (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	157
2	Social Sciences	2	2	97
3	Allergy	1	1	56
4	Anesthesia	1	1	56
5	Behavioral Sciences	1	1	54

Alexander McNamara

Publications

393

Citations

H-Index

Page 1

	Year	Citations
Impaired water maze learning performance without altered dopaminergic function in mice heterozygous for the GDNF mutation Robert Gerlai, Alexander McNamara, DL Choi-Lundberg, European Journal of Neuroscience	2001	127
Chronic fenoterol exposure increases in vivo and in vitro airway responses in guinea pigs. Zhong Lin Wang, Andrew M. Bramley, Alexander McNamara, American Journal of Respiratory and Critical Care Medicine AsthmaLung InflammationPharmacotherapyExperimental PharmacologyChronic Fenoterol Exposure	1994	56
Hippocampal dysfunction and behavioral deficit in the water maze in mice: An unresolved issue? Robert Gerlai, Alexander McNamara, Simon P. Williams, Brain Research Bulletin Neurobiological MechanismNeuropsychologyBehavioral SciencesWater MazeBehavioral Neuroscience	2002	54
Anesthesia induced retrograde amnesia is ameliorated by ephrinA5-IgG in mice: EphA receptor tyrosine kinases are involved in mammalian memory Robert Gerlai, Alexander McNamara Behavioural Brain Research Mammalian MemoryNeurophysiologyMedicineMemory LossAnesthetic Mechanism	2000	43
Discovery of (<i>R</i>)-1-(3-((2-Chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1′-Biphenyl]-2-ylcarbamate (TD-5959, GSK961081, Batefenterol): First-in-Class Dual Pharmacology Multivalent Muscarinic Antagonist and β<sub>2</sub> Agonist (MABA) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) Adam D. Hughes, Yan Chen, Sharath S. Hegde, Journal of Medicinal Chemistry Linker MotifLung InflammationPharmacotherapySystem PharmacologyPre-clinical Pharmacology	2015	34
In Vivo Pharmacological Characterization of TD-4208, a Novel Lung-Selective Inhaled Muscarinic Antagonist with Sustained Bronchoprotective Effect in Experimental Animal Models M. Teresa Pulido‐Rios, Alexander McNamara, Glenmar P. Obedencio, Journal of Pharmacology and Experimental Therapeutics	2013	28
Pharmacologic Characterization of GSK-961081 (TD-5959), a First-in-Class Inhaled Bifunctional Bronchodilator Possessing Muscarinic Receptor Antagonist and β2-Adrenoceptor Agonist Properties Sharath S. Hegde, Adam D. Hughes, Yan Chen, Journal of Pharmacology and Experimental Therapeutics	2014	17
Preclinical efficacy of THRX-200495, a dual pharmacology muscarinic receptor antagonist and β2-adrenoceptor agonist (MABA) Alexander McNamara, Tod Steinfeld, M. Teresa Pulido‐Rios, Pulmonary Pharmacology & Therapeutics Molecular Pharmacologyβ2-Adrenoceptor AgonistPharmacologyPreclinical EfficacyPharmacological Agent	2012	14
Duration by Design: Discovery of Revefenacin, the First-in-Class Nebulized Once-Daily Bronchodilator for the Treatment of Patients With COPD Yuhua Ji, Craig Husfeld, M. Teresa Pulido‐Rios, CHEST Journal AsthmaPulmonary CareAdvanced Lung DiseasePulmonary PharmacologyPulmonary Medicine	2016	10
Lung-restricted ALK5 inhibition avoids systemic toxicities associated with TGFβ pathway inhibition Jonathan Maher, Rui Zhang, Gopinath S. Palanisamy, Toxicology and Applied Pharmacology	2022	10

Page 1